{"result": "(\"entity\"<|>MELAS<|>EVENT<|>MELAS is a mitochondrial disease characterized by a range of symptoms including neurological, muscular, and gastrointestinal manifestations, often leading to malnutrition in affected individuals.)\n##\n(\"entity\"<|>NEW CASTLE<|>GEO<|>New Castle is associated with the scale of severity for adult mitochondrial diseases, specifically the NMDAS used to assess patients with MELAS.)\n##\n(\"entity\"<|>ARGININA<|>ORGANIZATION<|>Arginina is a therapeutic agent presumed to improve the availability of nitric oxide, potentially aiding in the treatment of MELAS symptoms.)\n##\n(\"entity\"<|>CITRULINA<|>ORGANIZATION<|>Citrulina is a supplement that increases nitric oxide production, which may have beneficial effects for patients with MELAS.)\n##\n(\"entity\"<|>COENZIMA Q10<|>ORGANIZATION<|>Coenzima Q10 is a compound that stabilizes the electron transport chain and has antioxidant properties, potentially benefiting patients with MELAS.)\n##\n(\"relationship\"<|>MELAS<|>NEW CASTLE<|>The severity of MELAS symptoms is assessed using the New Castle scale for mitochondrial diseases<|>7)\n##\n(\"relationship\"<|>MELAS<|>ARGININA<|>Arginina is used as a therapeutic agent to potentially alleviate symptoms of MELAS<|>6)\n##\n(\"relationship\"<|>MELAS<|>CITRULINA<|>Citrulina is considered for supplementation to enhance nitric oxide production in MELAS patients<|>6)\n##\n(\"relationship\"<|>MELAS<|>COENZIMA Q10<|>Coenzima Q10 is explored for its antioxidant effects that may help in managing symptoms of MELAS<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: incluyó a 92 pacientes evidenció que los síntomas gastrointestinales aumentan el riesgo de padecer malnutrición en portadores de la mutación m.3243A>G. En el 14% de la cohorte, el IMC fue inferior a 20 kg/m2 y, además, en aquellos con una puntuación elevada en la escala de gravedad de enfermedades mitocondriales de adultos de New Castle (NMDAS) este porcentaje aumentó hasta el 31%.\n\nA pesar de la frecuencia de manifestaciones digestivas y desnutrición en los pacientes con MELAS, la literatura es escasa en cuanto a su manejo, limitándose exclusivamente a estudios de cohortes sobre la descripción de los síntomas, pero sin indicar un tratamiento específico por la heterogeneidad del cuadro16.\n\n## Tabla 1. Manifestaciones clínicas del síndrome de MELAS10\n\n| Manifestaciones | Descripción |\n|-----------------|-------------|\n| 1. Neurológicas (>90%) | Cefaleas recurrentes, Episodios de Stroke-like (84-99%). Alteraciones neurológicas focales, autolimitadas y de duración incierta. Fundamentalmente occipitales (VISUALES). Epilepsia (71-96%) con presentación heterogénea. Hipoacusia neurosensorial (71-77%). Demencia (40-90%). Neuropatía periférica (22-77%). Manifestaciones psiquiátricas. |\n| 2. Musculares | Miopatía es la manifestación cardinal; intolerancia al ejercicio y debilidad muscular (73-100%). |\n| 3. Acidosis láctica (94%) | |\n| 4. Manifestaciones cardíacas (18-30%) | La más típica es una miocardiopatía hipertrófica. |\n| 5. Endocrinas | DM (21-33%). Talla baja (33-82%), deficiencia de hormona de crecimiento, hipotiroidismo, hipogonadismo, hipogonadotropo e hipoparatiroidismo. |\n| 6. Digestivas | Vómitos cíclicos (64-77%). Diarrea, estreñimiento, dismotilidad gástrica, pseudoobstrucción intestinal y pancreatitis recurrente. Fallo de medro (28%). |\n| 7. Hematológicas, renales, pulmonares, dermatológicas | |\n---\nEn cuanto al tratamiento específico de la enfermedad, muchos suplementos se han utilizado de forma experimental, pero pocos han sido probados en ensayos clínicos aleatorizados17. Los estudios se centran en:\n\n- **Dieta cetogénica**: parece reducir las crisis epilépticas en al menos la mitad de los pacientes tratados sin grandes efectos adversos, pero la seguridad a largo plazo y la efectividad en las enfermedades mitocondriales es desconocida. Podría ser de utilidad emplear dietas que sean menos restrictivas, aunque es necesario conocer el mecanismo fisiopatológico de la enfermedad en concreto18.\n\n- **Arginina**: su efecto terapéutico en este síndrome se presume que es debido a una mejora de la biodisponibilidad de NO, llevando a aumentar la vasodilatación cerebral y el flujo sanguíneo. Este mecanismo potencial se ha demostrado en niños y adultos en los cuales, la suplementación con arginina ha resultado en un aumento de NO determinado por técnicas de infusión de isótopos19,20. Además, se ha demostrado en ensayos clínicos aleatorizados abiertos que la administración intravenosa disminuye las crisis y produce una mejoría clínica. Por otro lado, la arginina oral durante las fases postictales también disminuyen la frecuencia y severidad de los episodios21,22.\n\n- **Citrulina**: los efectos clínicos de la citrulina no se han estudiado específicamente, sin embargo, la suplementación aumenta la producción de NO en adultos y niños19,20. Curiosamente, la citrulina incrementa en mayor proporción el NO, esto puede ser explicado porque amplifica la producción de arginina para que esté disponible y se transforme en NO. Tanto la arginina como la citrulina, tienen parámetros farmacocinéticos similares excepto por la concentración plasmática, que es mucho mayor en la citrulina, lo que hace pensar que tenga una mejor absorción y biodisponibilidad que la arginina23,24.\n\n- **Coenzima Q10 (CoQ10)**: facilita la trasferencia y estabiliza la cadena de transporte de electrones, aportando un efecto antioxidante protector que podría tener efectos beneficiosos en la debilidad muscular, la fatiga y los niveles de lactato en algunos pacientes con esta enfermedad25. CoQ10 no cruza la barrera hematoencefálica por lo que tiene un efecto limitado en el sistema nervioso central. La idebenona en un análogo del CoQ10 que puede cruzar esta barrera y ha\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}